South Africa’s Competition Tribunal has reportedly approved of the Nestle-Pfizer Nutrition baby formula merger, but with hard-hitting conditions, according to reports. Nestle and Pfizer stand as the largest and third-largest infant formula market in the country. The approval’s catch, however, requires a large divestment from Pfizer of its infant milk formula business, as the Tribunal found that the merger would leave only Aspen as a top competitor in the market. The Tribunal has included a list of concessions the parties need to address before the merger goes through. According to reports, remedies that have been suggested are similar to the remedies used to approve of the same deal in Australia; under the terms, Pfizer would reportedly divest its infant milk formula business in South Africa, and its new owner would rebrand the company and its products.
Featured News
Meta Halts Commercial Terms Rollout After Publishers Raise Concerns in EU, UK
Oct 28, 2026 by
CPI
Nvidia’s $12.9 Billion Hugging Face Deal Draws Justice Department Questions
Oct 28, 2026 by
CPI
Rolls-Royce’s UltraFan Wins £2.5 Billion UK Framework Deal
Oct 28, 2026 by
CPI
Taiwan Blocks Grab’s $600 Million Foodpanda Deal, Citing Uber Ties
Oct 28, 2026 by
CPI
South Korea Expands Food Price-Fixing Probe to Four Major Instant Noodle Makers
Oct 28, 2026 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Exclusive Dealing
Oct 25, 2026 by
CPI
Exclusive Dealing Without Exclusivity: Screening Contracts, Loyalty Rebates, and the Limits of Antitrust Tests
Oct 25, 2026 by
David Martimort & Jérôme Pouyet
When Competition for Exclusivity Raises Prices: Rebates, Pricing Rules, and the Insulin Puzzle
Oct 25, 2026 by
Daniel P. O’Brien & Greg Shaffer
Why Leaving the Door Open Can Be (Much) Worse Than Closing It: Share-Based Requirements, Buyer-Specific Costs, and Foreclosure
Oct 25, 2026 by
Zhijun Chen & Greg Shaffer
Antitrust Chronicle® – EU Merger Guidelines
Oct 19, 2026 by
CPI